Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oncotelic Therapeutics, Inc.MATN · Entity 7822 | Chief Financial Officer | June 20, 2018 | June 22, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oncotelic Therapeutics, Inc.
Report date June 20, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.22 · Expires 2028-06-20 | Direct | 250,000 |
Reported balance
After 2018-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-20 · Grant · Acquired 250,000 · Balance 250,000 F1: Mr. Loar was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "2017 Plan Options"), pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Financial Officer. F2: The Options will vest in twelve equal monthly installments beginning one month after the date of grant. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.22 · Expires 2028-06-20 | Direct | 500,000 |
Reported balance
After 2018-06-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-20 · Grant · Acquired 500,000 · Balance 500,000 F3: Mr. Loar was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "2015 Plan Options" and, collectively with the 2017 Plan Options, the "Options"), pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan in connection with his service as Chief Financial Officer. F2: The Options will vest in twelve equal monthly installments beginning one month after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Loar was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "2017 Plan Options"), pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Financial Officer.
F2: The Options will vest in twelve equal monthly installments beginning one month after the date of grant.
F3: Mr. Loar was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "2015 Plan Options" and, collectively with the 2017 Plan Options, the "Options"), pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan in connection with his service as Chief Financial Officer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2018 Filed Jun 22, 2018 20:12 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | GrantEmployee Stock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $0.22 | $0.00 |
DisclosureSEC source: 0001209191-18-039169 · doc4.xml · derivative · entry 2 LOAR MATTHEW M · CIK 0001236260 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-06-20 F3 · shares: Mr. Loar was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "2015 Plan Options" and, collectively with the 2017 Plan Options, the "Options"), pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan in connection with his service as Chief Financial Officer. F2 · derivative.exercise_date: The Options will vest in twelve equal monthly installments beginning one month after the date of grant. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 20:12 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.22 | $0.00 |
DisclosureSEC source: 0001209191-18-039169 · doc4.xml · derivative · entry 1 LOAR MATTHEW M · CIK 0001236260 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-06-20 F1 · shares: Mr. Loar was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "2017 Plan Options"), pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Financial Officer. F2 · derivative.exercise_date: The Options will vest in twelve equal monthly installments beginning one month after the date of grant. Read SEC document |
| April 12, 2018 Filed Apr 16, 2018 20:22 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | PurchaseCommon Stock B Warrant (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $0.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-024986 · doc4.xml · derivative · entry 3 LOAR MATTHEW M · CIK 0001236260 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires not disclosed F1 · price: The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the "Company"), dated April 12, 2018 (the "Subscription Agreement"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the "Common Stock"), (ii) an "A" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a "B" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share. F2 · derivative.exercise_date: The Common Stock B Warrants shall become exercisable immediately following the Company's stockholders' approval of an increase in the number of the Company's authorized shares of Common Stock sufficient to cover the number of shares issuable upon the exercise of all of the Common Stock B Warrants (the "Stock Authorization"). The Company is obligated to effect the Stock Authorization no later than June 30, 2018 (the "Authorization Date"). F3 · derivative.expiration_date: The Common Stock B Warrants shall expire on the date that is two years after the Stock Authorization is effected (the "Expiration Date"). In the event that the Company fails to effect the Stock Authorization by the Authorization Date, the Expiration Date will be extended for two additional years. Read SEC document |
| April 12, 2018 Filed Apr 16, 2018 20:22 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | PurchaseCommon Stock A Warrant (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $0.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-024986 · doc4.xml · derivative · entry 2 LOAR MATTHEW M · CIK 0001236260 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2020-04-12 F1 · price: The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the "Company"), dated April 12, 2018 (the "Subscription Agreement"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the "Common Stock"), (ii) an "A" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a "B" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share. Read SEC document |
| April 12, 2018 Filed Apr 16, 2018 20:22 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | PurchaseCommon Stock | 250,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-024986 · doc4.xml · nonDerivative · entry 1 LOAR MATTHEW M · CIK 0001236260 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 F1 · price: The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the "Company"), dated April 12, 2018 (the "Subscription Agreement"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the "Common Stock"), (ii) an "A" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a "B" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share. Read SEC document |
| January 12, 2017 Filed Jan 13, 2017 22:01 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | GrantEmployee Stock Option (Right to Buy) · Derivative | 350,000 | $0.38 Strike: $0.38 | $131,250.00 |
DisclosureSEC source: 0001209191-17-003702 · doc4.xml · derivative · entry 1 LOAR MATTHEW M · CIK 0001236260 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2027-01-12 F1 · shares: Mr. Loar was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share, pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Financial Officer. F2 · derivative.exercise_date: The Options will vest in forty-eight equal monthly installments beginning one month after the grant date. F1 · derivative.underlying_shares: Mr. Loar was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share, pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Financial Officer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.